Navigation Links
CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
Date:12/2/2011

KING OF PRUSSIA, Pa., Dec. 2, 2011 /PRNewswire/ -- CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders. CSL Behring has awarded more than $600,000 in grants to patient organizations since the LEAD program was established in 2008.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO)

The grant will be used to create the A-PLUS State Exchange Project, which will educate state advocates on the development of state insurance exchanges, including federally defined essential health benefits that establish the minimum requirements of exchanges.  The project will also help state advocates educate patients about implementation of the exchanges and how they can participate to ensure that access to specialized care and treatments will be maintained in the plans offered through the state insurance exchanges.

A-PLUS partners include:

  • Alpha-1 Association
  • Alpha-1 Foundation
  • Committee of Ten Thousand
  • GBS/CIDP Foundation International
  • Hemophilia Federation of America
  • Immune Deficiency Foundation
  • Jeffrey Modell Foundation
  • National Hemophilia Foundation
  • Patient Services Incorporated
  • Platelet Disorder Support Association

Larry LaMotte, Director of Government Affairs for the Immune Deficiency Foundation said, "This project will allow each organization's volunteers to be educated and trained to advocate effectively on behalf of their patient population and to make sure the development of state health exchanges provides protections for all patients with rare and chronic diseases. 

"The second benefit will be the development of trained patients to educate and assist other patients to be able to choose wisely the best insurance plans when the health care reform law goes into effect in January, 2014. The third benefit is that this project will allow the opportunity for plasma users of the different patient communities to work together as advocates in their respective states to affect the public policies that may affect them."

According to Michelle Rice, Regional Director for Chapter Services at the National Hemophilia Foundation, many of those affected by bleeding disorders have already been positively impacted by the new patient protections provided in the Affordable Care Act. "The expansion of state Medicaid programs and the creation of state health insurance exchanges in 2014 have the potential to offer consumers something many have never experienced – choices for health care coverage," Rice said.

CSL Behring's Senior Vice President of Public Affairs, Dennis Jackman added, "We are looking for opportunities to collaborate with patient organizations to advance advocacy initiatives. Providing a LEAD grant to A-PLUS for the state exchange project will positively impact patients represented by all the coalition members. The state insurance exchanges are a crucially important area where education and advocacy are needed, and we are very pleased to support this effort." 

LEAD grants are awarded semi-annually. CSL Behring considers grant proposals that relate to bleeding and platelet disorders, immune deficiencies, pulmonary disease and critical care. The submission deadline for the next round of grants is April 30, 2012. Applications, specific criteria for applying and more information about the LEAD program are available at www.cslbehring.com/leadgrants.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For information: www.cslbehring.com.

Contact:   

Chris Florentz, Manager Corporate Communications

 

610-878-4316   Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
2. CSL Behring Marks World Hemophilia Day by Announcing the Winners of the CSL Behring - Prof. Heimburger Award 2011
3. CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington
4. ProFibrix and CSL Behring Enter Into Fibrinogen and Thrombin Supply Agreement
5. CSL Behrings Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
8. BioCrossroads Awards Indiana Life Sciences Leaders
9. 1 Award Winner and 9 Prize Winners in the EFQM Business Excellence Awards
10. Cellular Dynamics Internationals (CDI) Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards
11. Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvanias Dr. Tejvir S. Khurana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... 2017  This year,s edition of the Inc. 5000 features a now-familiar ... solutions, has made the list for the third year in a row. ... private companies based on a set of quantitative metrics. In addition, BioPoint ... companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... 2017 , ... Any expert in stem cell research or stem cell medicine ... half a century. Despite their essential roles in human health and regenerative medicine, ... tags developed for this purpose also tag other, more abundant, non-stem tissue cells ( ...
Breaking Biology Technology:
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):